CME jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.
The 2019 AACI/CCAF Annual Meeting convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies. The three-day event aims to develop solutions to common challenges and to share best practices.

AACI welcomes Cancer Center at Illinois, in Urbana, as its newest member along with three new cancer center leaders on AACI’s board of directors, Drs. Carlos L. Arteaga, S. Gail Eckhardt, and Caryn Lerman. AACI extends its appreciation for the service of outgoing board members Drs. Dario C. Altieri, Benjamin G. Neel, and Eduardo Sotomayor.

We are pleased to recognize the research achievements of National Cancer Institute (NCI) Acting Director Dr. Douglas R. Lowy. In addition to receiving AACI’s Distinguished Scientist Award and detailing his recent lab work, Dr. Lowy will deliver the NCI Director’s Report on Tuesday. We will also honor the Jon M. and Karen Huntsman family with the AACI Champion for Cures Award, and the AACI Public Service Award will be presented to U.S. Representatives Kathy Castor (D-FL) and Fred Upton (R-MI).

This year's annual meeting program, jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF), includes an opening keynote talk by Devon Still, an advocate for childhood cancer awareness and a former professional athlete who will speak about his daughter's experience in overcoming cancer. I would like to offer a special thanks to Dr. Michael Kastan, who chaired the program committee.

The program also features panel discussions on a range of topics including artificial intelligence and Big Data, cancer center workforce training, alternative revenue and payment models, and community outreach and education. In addition, AACI is hosting its first CAR T-cell therapy symposium, and AACI President Dr. Roy A. Jensen will provide an update on his presidential initiative, a cancer-specific public policy resource library.

As I mark my first anniversary serving as the second executive director of AACI, I am honored to be part of a meeting that benefits so greatly from the hard work of many of you who volunteer your time and expertise to our committees and programs. Without you, and the dedication and skill of AACI’s staff, none of this would be possible.

The program also provides information on cancer research and patient care issues as they pertain to academic cancer center leaders, and provides them with a forum to discuss common issues. On behalf of the 2019 AACI/CCAF Annual Meeting Program Committee, welcome to Washington, DC.

Sincerely,
Jennifer W. Pegher
Executive Director
**Agenda**

*All sessions will be held in the Grand Ballroom, Lobby Level, except where indicated.*

**Sunday, October 20**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am</td>
<td>Registration Opens</td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Welcome and AACI Business Meeting</td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td></td>
<td><strong>Exhibits Open</strong></td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Opening Keynote</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Devon Still, an advocate for childhood cancer awareness and a former professional football player, will speak about his daughter’s experience in overcoming cancer. Leah Still, now 9 years old, was diagnosed with Stage IV neuroblastoma in 2014. After successful treatment, including participation in two clinical trials, she has been in remission for four years. Through the Still Strong Foundation, Devon Still has raised more than $2 million to provide assistance to families whose children are battling cancer.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mr. Devon Still</strong></td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Networking Break</td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Artificial Intelligence and Big Data: Shifting the Axis of Cancer Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technology's transformative impact on cancer research and care continues apace, with recent advances in the marriage of Big Data and electronic medical records, the use of artificial intelligence to detect cancer earlier, and partnerships between private biotech companies and academia. Panelists will describe recent experiences with technology implementation at their centers, including possible disruptions in the fields of pathology and radiology.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Dr. Warren Kibbe</strong></td>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Joel Saltz</strong></td>
<td>Stony Brook Cancer Center</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Jeremy Warner</strong></td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Georgia Tourassi</strong></td>
<td>Oak Ridge National Laboratory</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>7th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PCLI serves as a resource for creating best practices to help cancer center physician clinical leaders address a range of operational challenges while providing the best patient care. Panelists will discuss strategic initiatives that support and coordinate health research activities for sexual and gender minorities and address patient financial toxicity and its effect on patient care.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Dr. Randall F. Holcombe</strong></td>
<td>University of Hawai‘i Cancer Center</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Karen Parker</strong></td>
<td>University of Hawai‘i at Mānoa</td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Alan Balch</strong></td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td></td>
<td><strong>Patient Advocate Foundation</strong></td>
<td></td>
</tr>
<tr>
<td>4:00 pm</td>
<td>CCAF Business Meeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(closed session for members of CCAF)</td>
<td></td>
</tr>
<tr>
<td>6:00 – 7:30 pm</td>
<td>Welcome Reception</td>
<td>Promenade Foyer, Lobby Level</td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by Forte – Now an Advarra Company</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Program Subject to Change**
Monday, October 21

7:00 am  General Breakfast  
State Ballroom, Lobby Level

Cancer Center Directors Breakfast  
(Invitation Only)  
East Ballroom, Lobby Level

Exhibits Open  
Promenade, Lobby Level

8:00 am  Presidential Initiative Update: Public Policy Resource Library  
AACI cancer centers work together to reduce cancer incidence and mortality rates through research and sound public policy. To leverage the collective advocacy efforts of AACI members, AACI President Dr. Roy A. Jensen has spearheaded the development of a comprehensive online library of cancer-specific resources. It includes model legislation, communication tools, and educational materials to support advocates’ positions on topics such as the elimination of HPV related cancers, state funding for cancer research, and tobacco control. Dr. Jensen will showcase the initiative’s progress to date.

Dr. Roy A. Jensen  
The University of Kansas Cancer Center

8:30 am  Training the Cancer Center Workforce for 2030  
Numerous factors are significantly altering the cancer landscape: technology, an aging population, and advances in detection and treatment, to name a few. The need has never been greater to properly educate and maintain the oncology care workforce, ensuring that its size and competence is sufficient to maintain high standards at both the bench and bedside. Panelists will examine sustainable models for training both new physician scientists and clinical research staff. Administrative considerations such as funding fellowships will also be explored.

Moderator: Dr. Eric Fearon  
University of Michigan Rogel Cancer Center

Dr. Elizabeth Lawlor  
University of Michigan Rogel Cancer Center

Ms. Brenda Nevidjon  
Oncology Nursing Society

Dr. Sergey Radaev  
National Cancer Institute

9:45 am  Coffee Break – Sponsored by Huron  
Promenade Foyer, Lobby Level

10:00 am  Broadening Clinical Trial Eligibility Criteria  
The theme of AACI’s 2019 CRI annual meeting, Strategies to Maximize Innovation to Advance Cancer Clinical Research, recognized that innovation is necessary for institutional growth and for generating change in the clinical trials workplace. This CRI update session, led by CRI Steering Committee Chair Dr. Theresa Werner, will provide an overview of the 11th Annual CRI Meeting and CRI’s working groups. Extending the innovation theme, Dr. Edward Kim will discuss the ASCO-Friends of Cancer Research collaboration, “Broadening Eligibility Criteria to Advance Clinical Trial Recruitment.” This groundbreaking project involves the review of real-world data for revising trial eligibility criteria to make clinical trials more accessible and safer for patients.

Dr. Theresa Werner  
Huntsman Cancer Institute, University of Utah

Dr. Edward Kim  
Levine Cancer Center

10:45 am  2019 AACI Distinguished Scientist Award  
AACI will recognize Dr. Douglas R. Lowy, acting director of the National Cancer Institute, for his long-term research on the molecular biology of tumor viruses and growth regulation, which has been an invaluable resource for the cancer research community. Specifically highlighted is Dr. Lowy’s role in enabling the development of human papillomavirus vaccines (for which he won the 2017 Lasker-DeBakey Clinical Medical Research Award with colleague Dr. John Schiller), and his exploration of oncogenes and tumor suppressor genes and their signaling pathways as positive and negative regulators of normal and neoplastic growth.

Dr. Douglas R. Lowy  
National Cancer Institute

Program Subject to Change
11:45 am  **Awards Lunch**  
East & State Ballrooms, Lobby Level

**2019 AACI Public Service Award**  
The Honorable Kathy Castor (D-FL)  
The Honorable Fred Upton (R-MI)

**2019 AACI Champion for Cures Award**  
The Jon M. and Karen Huntsman Family

1:15 pm  **Networking and Dessert**  
Promenade Foyer, Lobby Level

1:45 pm  **Conflict of Interest Task Force Update**  
In response to growing concern over the integrity of cancer research, patient care, and the relationship between academic medicine and private industry, AACI convened a Conflict of Interest Task Force in early 2019. Task force co-chairs Drs. Leonidas Platanias and Karen E. Knudsen will share recommendations for cancer centers for disclosing and managing possible conflicts of interest for cancer center personnel and panelists will highlight their cancer center policies and a patient advocate perspective.

**Moderator:** Dr. Leonidas Platanias  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Dr. Karen E. Knudsen  
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Cornelia Ulrich  
Huntsman Cancer Institute, University of Utah

Ms. Patricia Wiley  
On the Wings of Angels

2:00 pm  **Welcome**  
Palm Court Ballroom, Lobby Level  
**Dr. Joseph McGuirk**  
The University of Kansas Cancer Center

**Keynote Presentation**  
Ms. Sydney Joorabchi, Patient Advocate  
The University of Kansas Cancer Center

2:30 pm  **Navigating the Health System to Establish and Administer a CAR T Program**  
**Moderator:** Mr. Clint L. Divine  
The University of Kansas Cancer Center  
**Dr. Matthew A. Lunning**  
Fred and Pamela Buffett Cancer Center  
University of Nebraska Medical Center  
**Mr. Thomas Mulder**  
UPMC Hillman Cancer Center  
**Mr. Robert Richards**  
Abramson Cancer Center of the University of Pennsylvania

3:30 pm  **Break**

3:45 pm  **Exploring the Value and Cost-Effectiveness of CAR T-Cell Therapy**  
**Moderator:** Dr. Matthew H. Carabasi  
Sidney Kimmel Cancer Center at Jefferson Health  
**Dr. Rena M. Conti**  
Boston University  
**Dr. Krishna Komanduri**  
Sylvester Comprehensive Cancer Center  
University of Miami Health System  
**Mr. Mark Trusheim**  
Massachusetts Institute of Technology

4:45 pm  **Closing Remarks**  
**Dr. Joseph McGuirk**  
The University of Kansas Cancer Center
Alternative Revenue Streams
Philanthropy and other private funding are major sources of financial support for cancer research. A growing number of cancer centers have developed sophisticated fundraising operations, with some centers benefiting from the services of hundreds of development professionals. Panelists will share best practices from development offices, highlighting public/private partnerships, working with consulting firms, and managing enhanced databases.

Moderator: Dr. Charles Fuchs
Yale Cancer Center
Yale School of Medicine

Dr. Scott Weir
The University of Kansas Cancer Center

Mr. Michael Weingarten
National Cancer Institute

Mr. John Glier
GG+A, Grenzebach Glier and Associates

3:30 pm Coffee Break
Promenade Foyer, Lobby Level

3:45 pm Concurrent Session
CCSG Nuts and Bolts
Optimal compliance with NCI Cancer Center Support Grant (CCSG) guidelines will be explored, with particular focus on selected cancer centers that have recently completed core grant submissions. The practical implications of preparing a CCSG competing renewal will be reviewed, and advice will be offered regarding different approaches for freestanding versus matrix cancer centers.

Moderator: Dr. Kimberly Kerstann
Winship Cancer Institute of Emory University

Mr. Robert Gerlach
Dartmouth-Hitchcock Norris Cotton Cancer Center

Ms. Karen Kharasch
Duke Cancer Institute
Duke University Medical Center

Dr. Wendy Law
Fred Hutchinson Cancer Research Center

Dr. Barbara Vance
Sylvester Comprehensive Cancer Center
University of Miami Health System

5:00 pm Sessions End

8:30 – 11:00 pm Hospitality – Sponsored by Complion
Palm Court Ballroom, Lobby Level

5:00 pm

7:00 am General Breakfast
State Ballroom, Lobby Level

Exhibits Open
Promenade Foyer, Lobby Level

Tuesday, October 22

8:30 am Topic-Specific Breakfast Roundtable Discussions
East Ballroom, Lobby Level

CAR T Clinical Trial Budgeting
Ms. Erin Williams
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Data Tables Open Discussion
Dr. Kimberly Kerstann
Winship Cancer Institute of Emory University
### Value-Based Reimbursement and Alternative Payment Models

To control rising health care costs, many cancer centers are experimenting with alternative payment models targeting specific clinical conditions, types of care, or populations. A prominent example is the Center for Medicare and Medicaid Services’ Oncology Care Model (OCM), which aims to provide higher quality, better coordinated oncology care at the same or lower cost as Medicare. Panelists will describe their experiences with OCM and other new payment strategies.

**Moderator:** Dr. Karen E. Knudsen  
Sidney Kimmel Cancer Center at Jefferson Health

### Emerging Centers

**Dr. Barbara Vance**  
Sylvester Comprehensive Cancer Center  
University of Miami Health System

**Inclusion Across the Lifespan**

**Mr. Robert Gerlach**  
Dartmouth-Hitchcock Norris Cotton Cancer Center

**Implementing the Shared Investigator Platform (SIP) at Your Cancer Center**

**Mr. Hobs Apell**  
The University of Kansas Cancer Center

**Ms. Jessica Moehle**  
Huntsman Cancer Institute, University of Utah

**Introduction to AACI’s Physician Clinical Leadership Initiative (PCLI)**

**Dr. Randall F. Holcombe**  
University of Hawai‘i Cancer Center  
University of Hawai‘i at Mānoa

**Logistics of a Community Outreach and Engagement (COE) Office**

**Mr. Alex Zafirovski**  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

**New Administrator Networking**

**Ms. Karen Kharasch**  
Duke Cancer Institute  
Duke University Medical Center

**Tools for Tracking Trainees for Career Enhancement Activities**

**Dr. Wendy Law**  
Fred Hutchinson Cancer Research Center

### Community Outreach and Engagement

Motivated by community outreach and engagement (COE) mandates in the CCSG application, many cancer centers have sharpened their commitment to finding ways to extend cutting-edge care and strengthen ties to a broader pool of patients and stakeholders. This session will highlight the structure and implementation of innovative COE efforts such as new technology platforms (e.g., registry databases). COE in various settings—small versus large cancer centers, rural versus urban facilities—will also be considered.

**Moderator:** Dr. Cheryl Willman  
University of New Mexico Comprehensive Cancer Center

**Dr. Elizabeth Gage-Bouchard**  
Roswell Park Comprehensive Cancer Center

**Dr. Nadine Barrett**  
Duke Cancer Institute  
Duke University Medical Center

**Dr. Erin Kobetz**  
Sylvester Comprehensive Cancer Center  
University of Miami Health System

### Coffee Break

**10:00 am**  
**Promenade Foyer, Lobby Level**

### NCI Director’s Report

The acting director of the National Cancer Institute (NCI) will share the latest NCI budget and priorities as well as updates on new and ongoing initiatives that influence the work of academic cancer centers.

**Dr. Douglas R. Lowy**  
National Cancer Institute

### Update on the NCI Cancer Centers Program

This session provides an opportunity for an open dialogue with the director of the NCI Office of Cancer Centers about the requirements and funding of the CCSG.

**Dr. Henry P. Ciolino**  
National Cancer Institute

### Adjourn

**12:00 pm**
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

Accreditation
This activity has been planned and implemented in accordance with the accreditation policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI). AACR is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation
AACR designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live CME activity must complete the CME Request for Credit Survey by November 5, 2019. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

1. The facilitation of technological advances in cancer research and care through collaborative relationships between academia and industry
2. Innovative solutions to a wide spectrum of administrative challenges for cancer center physician clinical leadership
3. The value of an online library of cancer-specific legislation resources to the development of sound public policy
4. The effects of technology, an aging population, and advances in detection and treatment on training and engaging the cancer center workforce
5. Progress of the AACI Clinical Research Innovation (CRI) program
6. The impact of translational research on the human papillomavirus (HPV), which led to the development of the HPV vaccine
7. Best practices for disclosing and managing potential conflicts of interest for cancer center personnel
8. The cultivation of alternative revenue streams for cancer centers
9. Compliance with current NCI CCSG guidelines
10. The development of metastasis prevention agents and novel approaches to liquid biopsy
11. Alternative payment models adopted by some cancer centers, including those targeting specific clinical conditions, types of care, or populations
12. The implementation of innovative community outreach and engagement (COE) efforts and technology platforms in a variety of settings
13. The NCIs priorities, policies, strategies, and goals for the national cancer research enterprise, and their relationship to academic cancer centers
14. Challenges and opportunities for collaboration between academia, government, and the private sector

Americans with Disabilities Act
It is the policy of AACR and AACI not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act to fully participate in this CME activity, please contact 412-647-6111 or attach a note to your registration form.

Disclosure Statement
It is the policy of AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Target Audience
This transdisciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects. All attendees have a significant impact on cancer research and patient care.

Attendees may include:
- Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical staff
- Leaders from industry and government agencies as well as those of cancer research and advocacy organizations
- Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, and psychologists
- Social workers, cancer communication specialists, public health leaders, and faculty members who focus on cancer
2019 AACI Distinguished Scientist Award

Dr. Douglas R. Lowy
National Cancer Institute

Dr. Douglas R. Lowy is acting director of the National Cancer Institute (NCI). AACI is recognizing Dr. Lowy for his long-term research on the molecular biology of tumor viruses and growth regulation, his role in enabling the development of human papillomavirus (HPV) vaccines, and his exploration of oncogenes and tumor suppressor genes and their signaling pathways.

Dr. Lowy was named NCI’s acting director in April 2019 following the appointment of then-NCI Director Dr. Norman Sharpless, as acting commissioner of the U.S. Food and Drug Administration. He is also chief of the Laboratory of Cellular Oncology in NCI’s Center for Cancer Research and served as acting director of NCI from April 2015 to October 2017. Prior to these appointments, Dr. Lowy had held the NCI deputy director position since 2010.

Dr. Lowy’s current research examines the DLC1 tumor suppressor, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. This work has identified important scaffold functions for DLC1, including protein-protein interactions that contribute to the regulation of its activity and its role as a tumor suppressor, and identified kinases that activate and inactivate the functions of DLC1 and the mechanisms by which they do so. Dr. Lowy also continues to pursue research on HPV.

In 2014, Dr. Lowy, with his colleague Dr. John Schiller, received the National Medal of Technology and Innovation. In 2017, the scientists received the Lasker-DeBakey Clinical Medical Research Award, the country’s most prestigious honor for biomedical research, for their significant research leading to the development of HPV vaccines.

Recent AACI distinguished scientist honorees include Drs. Charles Perou, Carl June, James Allison, Lewis Cantley, Tim Ley, Brian Druker, Lee Hartwell, and Mary-Claire King.

2019 AACI Champion for Cures Award

The Jon M. and Karen Huntsman Family

The Jon M. and Karen Huntsman family will receive AACI’s 2019 Champion for Cures Award, in recognition of their significant leadership in supporting efforts to cure cancer and in inspiring others to do the same.

The Huntsman family’s first major gift to cancer research came in 1993 at $10 million, followed by a $100 million gift in 1995 that formally established and named the Huntsman Cancer Institute (HCI) at the University of Utah. At the time, this was the largest gift ever given by a single individual to support medical research.

At the outset of his philanthropy, Jon M. Huntsman envisioned a time when all would participate in and financially support the cancer institute. He went on to found Huntsman Cancer Foundation (HCF) to engage a community of donors in investing in cancer research. Today, HCF enjoys the support of more than one million donors from all states across the nation, and has substantial assets to serve as an endowment for the cancer institute’s future. Peter R. Huntsman serves as chairman and CEO of HCF.

The Huntsman family and HCF have made many substantial contributions to cancer research and care at HCI. These include a commitment of $120 million by HCF in 2017. Following Jon M. Huntsman’s death in February 2018, the legacy continued, as less than a year later, the family announced a $30 million gift from the Huntsman Foundation alongside more than $42 million raised by HCF from other donors to support a hospital expansion at HCI. This expansion, planned to open in 2022, will focus on women’s cancers and integrative health. In all, the family has donated or inspired donations totaling $1.4 billion to cancer.
2019 ACSI Public Service Award

**The Honorable Kathy Castor (D-FL)**
U.S. House of Representatives

Representative Castor has made a profound impact on cancer prevention in Florida by initiating and sustaining a long-term campaign to raise awareness of cancers related to the human papillomavirus (HPV) and the HPV vaccine.

Since 2013, Rep. Castor has collaborated with stakeholders throughout Florida—including community health centers, public health colleges, nonprofit organizations, places of worship, and civic groups—to increase rates of HPV vaccination. As a result of Rep. Castor’s commitment, HPV vaccination rates in Florida have increased significantly. She is currently developing federal legislation aimed at increasing HPV vaccination nationwide. This represents a major step toward the elimination of cervical cancer, with other HPV-related cancers to follow.


**The Honorable Fred Upton (R-MI)**
U.S. House of Representatives

Representative Upton is a strong supporter of biomedical research in general, and cancer research in particular.

Alongside Rep. Diana DeGette (D-CO), Rep. Upton co-authored the 21st Century Cures Act, which increased federal funding for the NIH and the NCI to accelerate the development of medical products, drugs, and devices to benefit patients. Both legislators were honored by ACSI in 2015 for their role in developing the legislation, which was signed into law by President Barack Obama in 2016.

As a member of the House Childhood Cancer Caucus, Rep. Upton advocates in support of measures to raise awareness of pediatric cancers and reduce their negative long-term effects. In 2018 he co-sponsored the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, the most comprehensive childhood cancer legislation ever taken up by Congress.

Keynote Speaker

**Devon Still**
Still Strong Foundation

Devon Still, an advocate for childhood cancer awareness and a former professional football player, will deliver the keynote address on Sunday, October 20, describing his daughter’s experience overcoming cancer.

Mr. Still played football for the Houston Texans and Cincinnati Bengals and was a Penn State University All-American and Big Ten Defensive Player of the Year. When his daughter Leah was diagnosed with a rare pediatric cancer in 2014—two months after Still almost died from post-back surgery blood clots in his lungs—he returned to the football field wearing Leah’s message of hope, “Don’t be scared, be strong,” during every game. Their fight has inspired many cancer patients, along with their families and friends, now, through the Still Strong Foundation, Still has raised more than $2 million and is influencing the global cancer conversation.

Growing up on the streets of Wilmington, Delaware, Still was the first person in his family to graduate from college and was selected in the 2012 National Football League draft by the Bengals. Today, Still is an author, peak performance coach, and motivational speaker. He has received numerous accolades including People Magazine’s 2016 Dad of the Year award, the 2018 Penn State Alumni Achievement Award for most successful alumni under 30, and the 2019 American Icon Award.

Leah Still, now nine years old, was diagnosed with Stage IV neuroblastoma at the age of four. After being given a 50/50 chance to live, she entered a clinical trial specifically targeting neuroblastoma cells. Her treatment included weeks of intensive chemotherapy, radiation therapy, surgery, and additional experimental measures.

After completing chemotherapy, Leah underwent a seven-hour procedure to remove her tumor. Despite the surgery, the disease continued to spread. Treatment in another clinical trial, which used an antibody treatment to destroy her cancer, was successful, and Leah has been in remission for four years.
The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**Forte – Now an Advarra Company**
Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems.

With a strong belief in community, collaboration, and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research.

Forte provides all research professionals complimentary blog articles, eBooks, webinars, and more to support continuous learning on industry topics.

Forte was recently acquired by Advarra, the premier provider of institutional review board (IRB), institutional biosafety committee (IBC), and global research compliance consulting services. The combined organization leverages mutual strengths in supporting the research community with client service, regulatory expertise, and technology-enabled efficiencies to accelerate innovation, streamline research operations, support faster study start-up, and help make research altogether better.

**Agilent Technologies, iLab Operations Software**
iLab Operations Software, a part of the Agilent CrossLab family, is an enterprise web-based management tool designed to support operations for centralized shared research resources. Its functionality includes service request and milestone management, storeroom management, sample processing, equipment reservation management, usage tracking, billing and invoicing, reporting, lab requisitioning, and spend tracking tools. The Agilent team has extensive experience integrating iLab with institutional financial and identity management systems. As part of the full CrossLab capability, more than 1,000 Core facilities and other shared research resources across over 170 organizations in North America, Europe, and the Asia-Pacific region rely on the iLab software to streamline operations.

**Caris Life Sciences©**
Caris Life Sciences© is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

**Cejka Search**
Cejka Search is dedicated to recruiting leaders in the fight against cancer and improving the quality of patient care for those confronting cancer. We partner with cancer centers to recruit outstanding cancer science leaders including directors, associate directors, program leaders, physician scientists, basic, clinical and translational research scientists, and administrators. We strive to remain involved, informed, and educated in the work of professional organizations dedicated to cancer research and patient care and are a proud supporter of AACI and CCAF.

Our Cancer Science and Care Leadership Practice is led by Alan D. Johns, executive vice president/managing principal. He brings direct experience in cancer center and research administration to the table through his leadership experience at two NCI-Designated Cancer Centers. Since entering executive search several years ago, Mr. Johns has specialized in cancer center leadership recruitment while maintaining his relationship with many of the nation's cancer center directors, cancer research scientists and administrators.

**Complion**
Complion's industry-leading eRegulatory document and workflow management platform improves efficiency, compliance, and transparency for research sites and sponsors. The sponsor-approved, turn-key platform stores, organizes, and routes all of the regulatory documentation involved in a clinical trial. On average, Complion's customers save over $6,000 per trial because staff members spend less time chasing down paper, and physical materials, along with storage space, are no longer needed. Complion has garnered overwhelming industry support and has been accessed by more sponsors and CROs than any other eRegulatory platform. More than 5,200 clinical trials have been managed and stored in Complion.

**DEEP 6 AI®**
Deep 6 AI® uses artificial intelligence and natural language processing on medical records so you can find and validate the patients you need to run a successful trial—in a matter of minutes.

Designed to put recruitment power into the hands of researchers, Deep 6 transforms trial criteria into an AI-powered search query. The tool then lets research staff search both structured and unstructured medical data—like physician's notes and pathology reports—so they can find and screen more, better-matching patients for their most complex trials more quickly.

The Deep 6 platform is EMR-agnostic and allows users to identify, screen and recruit patients in a HIPAA and IRB-compliant manner.

Deep 6 AI was founded in 2015 and is based in Pasadena, CA. Come visit our table or find out more at: https://deep6.ai/
ECG Management Consultants
Collaborating with the oncology community for over 30 years, ECG supports clients with the information required to successfully achieve oncology strategic, operational, and performance improvement goals. ECG’s oncology consulting engagements support both academic and community-based cancer programs and cancer centers. In July of 2019 ECG welcomed Oncology Resource Consultants to our oncology practice, expanding the breadth and depth of the firm’s experience, establishing our position as industry leaders in collaborating with the cancer community to lead oncology forward. Learn more about ECG’s cancer services by visiting our website at: www.ecgmc.com/cancer

Florence
Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence eBinders is trusted by 5,000+ Investigators to manage eRegulatory and eSource for over 2,500 studies and is the leading solution for cancer institutes. Florence eHub is revolutionizing site-sponsor connectivity in a virtual site workspace for site oversight, monitoring, startup, and quality control.

Huron
Huron is a global professional services and software firm committed to achieving sustainable results in partnership with its clients. The company brings depth of expertise in strategy, technology, operations, advisory services and analytics to drive lasting and measurable results in the health care, higher education, life sciences and commercial sectors. Through focus, passion, and collaboration, Huron provides guidance to support organizations as they contend with the change transforming their industries and businesses.

Idea Elan
Idea Elan is one of the fastest growing companies in the field of core facility management.

Our flagship product Infinity Core Management software has successfully streamlined the management of hundreds of core facilities worldwide. We provide enterprise web application with stunning user interface to enhance your lab and core facility productivity.

Infinity is selected by many comprehensive cancer centers such as Salk Institute, Lombardi Cancer Center (Georgetown University), Barbara Ann Karmanos Cancer Institute (Wayne State University), Medical University of South Carolina (MUSC), and more.

Key benefits to our customers are:

a. Out of the box solution that meets more than 95% of requirements
b. Completely flexible and configurable by institution & facility administrators without vendor support
c. Customers go live within a few weeks using Infinity
d. Dedicated Infinity mobile app to work on the go
e. We provide complete integration with your financial systems such as Oracle, PeopleSoft, SAP, Workday, etc
f. Dedicated support team to handhold the entire implementation process
g. We can integrate with any SSO such as AD, LDAP, Shibboleth etc
h. We have over 18 different modules, including an animal facility management module, to meet all needs

Visit us at www.IdeaElan.com to learn more.

Merck
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Patient Resource LLC
Patient Resource’s innovative, advanced patient education platform offers hospitals and cancer centers the opportunity to improve the patient experience before treatment even starts. Providing uniquely developed guides and apps for each center and each patient, this system offers you a way to instantly decrease patient anxiety. The comprehensive materials introduce the care team and outline everything needed from personal diagnosis to treatment care plans on to survivorship guidance. The one-to-one patient app offers PRO solutions to medication adherence and treatment-related symptom management. Including powerful administrative reporting and cost analysis tools, Patient Resource Navigator ensures standardized personal touchpoints for all clinic teams and locations.

Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.
The Tumor Imaging Metrics Core (TIMC) of the Dana-Farber/Harvard Cancer Center (DF/HCC) has increased the quality and efficiency of imaging assessments by developing a cloud-hosted informatics solution, branded Precision Imaging Metrics. The platform includes a clinical trial imaging assessment and workflow management system and integrated web-viewer that improves protocol adherence by eliminating common response criteria discrepancies and accelerates tumor measurements turnaround time to support same-day reporting. Our all-in-one solution streamlines communication between radiology and cancer center teams, manages the financial components of imaging assessments, and provides electronic signatures and change controls to support audits.

The Precision Imaging Metrics (PIM) system has built-in flexibility to allow for site customization to better meet the specific imaging review needs of each cancer center and provides standardized training and protocol review resources to ensure trials are consistently executed across all PIM sites. The system is available through an academic licensing model and is currently in use at eight NCI-Designated Cancer Centers across the country as an NCI-shared resource. Please email support@precisionmetrics.org to schedule a demo.

WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry’s first clinical services organization, WCG offers solutions that accelerate the delivery of new therapies to patients. WCG is pleased to welcome PFS Clinical (PharmaSeek) and Velos into our family of companies.

WCG PFS Clinical is dedicated to helping research institutions improve the management of their clinical trials from study start-up to final payment. Our Initiate service line provide on-demand study initiation services for contracts, budgets, coverage analyses, negotiations, and CTMS calendar builds. With RevGuard, we manage your research billing processes, including financial tracking/reconciliation, financial reporting, and claims review, so you can focus on patient outcomes. Our Boost consultants collaborate with your team to improve your research programs through workflow redesign, physician compensation plans, and flexible education and training.

WCG Velos offers global, clinical research management software (CRMS) for cancer centers, academic medical centers, hospitals, health systems, clinical research sites, and sponsors. For more than two decades, Velos has facilitated efficiency, quality, and compliance in clinical research with a focus on cancer centers, supporting study and protocol management, electronic data capture, financial management, protocol review and IRBs, biospecimen management, and more.

We invite AACI members to join the WCG Global Research Network™ (GRN) which provides clinical researchers with access to sponsors and peer sites for collaboration and visibility. Through WCG’s unique relationship with sponsors, CROs, research sites, and patient advocacy groups, GRN member sites benefit from our knowledge-based benchmarking insights and professional development opportunities.
Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Company</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anderson</td>
<td>Jaime</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Balch</td>
<td>Alan</td>
<td>Patient Advocate Foundation</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Barrett</td>
<td>Nadine</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Brasiliños</td>
<td>Priscilla</td>
<td>Massachusetts General Hospital</td>
<td>Merck, Genentech-Roche, Lilly, Angiochem, BMS</td>
<td>G,H,C</td>
<td>Speaker</td>
</tr>
<tr>
<td>Chapman</td>
<td>Andrew</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Cinikha</td>
<td>Henry</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Davis</td>
<td>Jeffrey</td>
<td>Baker Donelson</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Fearon</td>
<td>Eric</td>
<td>University of Michigan Rogel Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Fuchs</td>
<td>Charles</td>
<td>Yale Cancer Center, Yale School of Medicine</td>
<td>Ajoios, Bain Capital, Bayer, Celgene, Dicerna, Eli Lilly, Fos Prime Therapeutics, Genentech, Sited Sciences, KSN, Merck, Memmack Pfizer, Roche, Sanofi, Taiho, Ushin, Gocyma, Entirewise Health</td>
<td>A,C,D</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Gage-Bouchard</td>
<td>Elizabeth</td>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Gerlach</td>
<td>Robert</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Giler</td>
<td>John</td>
<td>SgesA, Grenebach Giler and Associates</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Holacker</td>
<td>Jarie</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Holcombe</td>
<td>Randall</td>
<td>University of Hawai’i Cancer Center, University of Hawai’i at Mānoa</td>
<td>Merck</td>
<td>O,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jensen</td>
<td>Roy</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Kastan</td>
<td>Michael</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Kentman</td>
<td>Kimberly</td>
<td>Winship Cancer Institute of Emory University</td>
<td>Medical College of South Carolina, University of Virginia, University of Rochester</td>
<td>A</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Kharsach</td>
<td>Karen</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>Forte</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kibbe</td>
<td>Warren</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kim</td>
<td>Edward</td>
<td>Levine Cancer Center</td>
<td>Roche, Boehringer Ingelheim, Pfizer, AstaZeneca, Merck</td>
<td>A,N</td>
<td>Speaker</td>
</tr>
<tr>
<td>Knudson</td>
<td>Karen</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>CellCerica, Genentech, Alsun, Celgene, Janssen</td>
<td>A,C,G,H,SB</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Koboetz</td>
<td>Erin</td>
<td>Sylvester Comprehensive Cancer Center, University of Miami Health System</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Law</td>
<td>Wendy</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Lawlor</td>
<td>Elizabeth</td>
<td>University of Michigan Rogel Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Leach</td>
<td>Steven</td>
<td>Dartmouth College, Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>Epitome Diagnostics, Nybo Therapeutics</td>
<td>C</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Loyy</td>
<td>Douglas</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Mitchell</td>
<td>Robert</td>
<td>University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Needham</td>
<td>Brenda</td>
<td>Oncology Nursing Society</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Parker</td>
<td>Karen</td>
<td>National Institutes of Health</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Pegher</td>
<td>Jennifer</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Platoons</td>
<td>Leonidas</td>
<td>Robert H. Lue Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Pollock</td>
<td>Raphael</td>
<td>The Ohio State University Comprehensive Cancer Center – The James</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Polysak</td>
<td>Kornelia</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Mita Biotech, Avaron Therapeutics, Blueprint Medicine</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Radljev</td>
<td>Serge</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Salz</td>
<td>Joel</td>
<td>Stony Brook Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Shumate</td>
<td>Kate</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Smedley</td>
<td>Warren</td>
<td>Deep South Cancer Foundation</td>
<td>Genentech USA</td>
<td>G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Still</td>
<td>Devon</td>
<td>Independent Advocate (Still Strong Foundation)</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Tourassi</td>
<td>Georgios</td>
<td>Oak Ridge National Laboratory</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Urish</td>
<td>Cornelia</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Vance</td>
<td>Barbara</td>
<td>Sylvester Comprehensive Cancer Center, University of Miami Health System</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Velculescu</td>
<td>Victor</td>
<td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</td>
<td>Personal Genome Diagnostics, Delf Diagnostics, Takeda</td>
<td>A,C,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Warner</td>
<td>Jeremy</td>
<td>Vanderbilt-Ingram Cancer Center</td>
<td>Westal, HemOnC.org LLC, IBM Watson Health</td>
<td>A,C,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Weinigarten</td>
<td>Michael</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Weir</td>
<td>Scott</td>
<td>The University of Kansas Cancer Center</td>
<td>GoldMed LLC, PB 360 International</td>
<td>O,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Werner</td>
<td>Theresa</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Wiley</td>
<td>Patricia</td>
<td>On the Wings of Angels</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Willman</td>
<td>Cheryl</td>
<td>University of New Mexico Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Zafirosik</td>
<td>Aleksandar</td>
<td>Robert H. Lue Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
</tbody>
</table>

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock shareholder; SB, Speakers’ bureau; H, Honoraria; O, Other.
## CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Claimed Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday 10/20/19</td>
<td>1:30 – 2:30 pm</td>
<td>Opening Keynote: Devon Still</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:00 – 4:00 pm</td>
<td>Artificial Intelligence and Big Data: Shifting the Axis of Cancer Care</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:00 – 6:00 pm</td>
<td>7th Annual AACI PCLI Meeting</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Maximum Approved Credits for 10/20/19</strong></td>
<td><strong>4.0</strong></td>
<td><strong>TOTAL:</strong></td>
</tr>
<tr>
<td>Monday 10/21/19</td>
<td>8:00 – 8:30 am</td>
<td>AACI Presidential Initiative Update: Public Policy Resource Library</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 – 9:45 am</td>
<td>Training the Cancer Center Workforce for 2030</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00 – 10:45 am</td>
<td>Broadening Clinical Trial Eligibility Criteria</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:45 – 11:45 am</td>
<td>Distinguished Scientist: Dr. Douglas R. Lowy</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:45 – 2:30 pm</td>
<td>Conflict of Interest Task Force Update</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:30 – 3:30 pm</td>
<td>Alternative Revenue Streams</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:45 – 5:00 pm</td>
<td>CCSG Nuts and Bolts (concurrent)</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stopping the Spread: Advances in Understanding and Detecting Tumor Metastasis (concurrent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/21/19</strong></td>
<td><strong>6.5</strong></td>
<td><strong>TOTAL:</strong></td>
<td></td>
</tr>
<tr>
<td>Tuesday 10/21/19</td>
<td>8:00 – 9:00 am</td>
<td>Value-Based Reimbursement and Alternative Payment Models</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:00 – 10:00 am</td>
<td>Community Outreach and Education</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:15 – 11:15 am</td>
<td>NCI Director’s Report</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:15 – Noon</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/22/19</strong></td>
<td><strong>3.75</strong></td>
<td><strong>TOTAL:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum CME Credits Approved</strong></td>
<td><strong>14.25</strong></td>
<td><strong>TOTAL:</strong></td>
<td></td>
</tr>
</tbody>
</table>

## Support

### Acknowledgment of Commercial Support

The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Foundation Medicine
- Genentech
- Genomic Health
- Gilead
- Merck
- Novartis
- Pfizer
- Varian Medical Systems

### Acknowledgment of Programmatic Support

AACI gratefully acknowledges the following organizations for providing program and activity support:

- AbbVie
- Forte – Now an Advarra Company
- Amgen
- Astellas
- Bristol-Myers Squibb
- Complion
- Florence
- Genentech
- Huron Consulting Group
- Janssen Research & Development
- Kite
- Lilly
- Merck
- Pfizer
- Takeda Oncology

*Support as of September 30, 2019*
2020 Meetings — Save the Date

July 7–9, 2020
Loews Chicago O'Hare Hotel

October 11 – 13, 2020
Intercontinental Kansas City at The Plaza